Direct Immunochemiluminescent Assay for proBNP and Total BNP in Human Plasma proBNP and Total BNP Levels in Normal and Heart Failure

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Nishikimi, Toshio ^a   Okamoto, Hiroyuki ^b   Nakamura, Masahiro ^b   Ogawa, Naoko ^b   Horii, Kazukiyo ^b   Nagata, Kiyoshi ^b   Nakagawa, Yasuaki ^a   Kinoshita, Hideyuki ^a   Yamada, Chinatsu ^a   Nakao, Kazuhiro ^a   Minami, Takeya ^a   Kuwabara, Yoshihiro ^a   Kuwahara, Koichiro ^a   Masuda, Izuru ^c   Kangawa, Kenji ^d   Minamino, Naoto ^d   Nakao, Kazuwa ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SHIONOGI AND CO LTD   (Japan)

^c Takeda Hospital Medical Examination Center   (Japan)

^d NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; GLYCOSYLATED AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 18H5; MONOCLONAL ANTIBODY BC203; MONOCLONAL ANTIBODY KY BNP II; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE BLOOD LEVEL; ANTIGEN RECOGNITION; ARTICLE; CHEMILUMINESCENCE IMMUNOASSAY; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS REACTION; DEGLYCOSYLATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DILUTION CURVE; FEMALE; GEL FILTRATION CHROMATOGRAPHY; HEART FAILURE; HUMAN; LIMIT OF DETECTION; LINEAR SYSTEM; MALE; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CALIBRATION; CASE-CONTROL STUDIES; CROSS REACTIONS; EARLY DIAGNOSIS; FEMALE; HEART FAILURE; HUMANS; IMMUNOASSAY; LIMIT OF DETECTION; LUMINESCENT MEASUREMENTS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; OBSERVER VARIATION; PROTEIN PRECURSORS; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS;

EID: 84872862787     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0053233     Document Type: Article

References (19)

1. Maisel AS, Nakao K, Ponikowski P, Peacock WF, Yoshimura M, et al. (2011) Japanese-Western consensus meeting on biomarkers. Int Heart J 52: 253-65.
2. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, et al. (2009) ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119: 1977-2016.
3. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, et al. (2008) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). ESC Committee for Practice Guidelines (CPG). Eur Heart J 29: 2388-442.
4. Minamino N, Horio H, Nishikimi T (2006) Chapter 165. Natriuretic peptides in the cardiovascular system. In: Kastin AJ, editor. THE HANDBOOK OF BIOLOGICALLY ACTIVE PEPTIDES. 1st ed. Academic Press, pp. 1217-1225.
5. Waldo SW, Beede J, Isakson S, Villard-Saussine S, Fareh J, et al. (2008) Pro-B-type natriuretic peptide levels in acute decompensated heart failure. J Am Coll Cardiol 51: 1874-82.
6. Nishikimi T, Minamino N, Ikeda M, Takeda Y, Tadokoro K, et al. (2010) Diversity of molecular forms of plasma brain natriuretic peptide in heart failure-different proBNP-108 to BNP-32 ratios in atrial and ventricular overload. Heart 96: 432-9.
7. Liang F, O'Rear J, Schellenberger U, Tai L, Lasecki M, et al. (2007) Evidence for functional heterogeneity of circulating B-type natriuretic peptide. J Am Coll Cardiol 49: 1071-8.
8. Nishikimi T, Minamino N, Horii K, Matsuoka H, (2007) Do commercially available assay kits for B-type natriuretic peptide measure Pro-BNP1-108, as well as BNP1-32? Hypertension 50: e163.
9. Semenov AG, Seferian KR, (2011) Biochemistry of the human B-type natriuretic peptide precursor and molecular aspects of its processing. Clin Chim Acta 412: 850-60.
10. Tsuji T, Inouye K, Yamauchi A, Kono M, Igano K (2004) U.S. Patent 6, 677, 124 B2, pp 16, Shionogi Seiyaku Kabushiki Kaisha, Japan.
11. Seferian KR, Tamm NN, Semenov AG, Tolstaya AA, Koshkina EV, et al. (2008) Immunodetection of glycosylated NT-proBNP circulating in human blood. Clin Chem 54: 866-73.
12. Ishikawa E, Imagawa M, Hashida S, Yoshitake S, Hamaguchi Y, et al. (1983) Enzyme-labeling of antibodies and their fragments for enzyme immunoassay and immunohistochemical staining. J Immunoassay 4: 209-327.
13. Nishikimi T, Ikeda M, Takeda Y, Ishimitsu T, Shibasaki I, et al. (2012) The effect of glycosylation on plasma N-terminal proBNP-76 levels in patients with heart or renal failure. Heart 98: 152-61.
14. Schellenberger U, O'Rear J, Guzzetta A, Jue RA, Protter AA, et al. (2006) The precursor to B-type natriuretic peptide is an O-linked glycoprotein. Arch Biochem Biophys 451: 160-6.
15. Nishikimi T, Kuwahara K, Nakao K, (2011) Current biochemistry, molecular biology, and clinical relevance of natriuretic peptides. J Cardiol 57: 131-40.
16. Seferian KR, Tamm NN, Semenov AG, Mukharyamova KS, Tolstaya AA, et al. (2007) The brain natriuretic peptide (BNP) precursor is the major immunoreactive form of BNP in patients with heart failure. Clin Chem 53: 866-73.
17. Hammerer-Lercher A, Halfinger B, Sarg B, Mair J, Puschendorf B, et al. (2008) Analysis of circulating forms of proBNP and NT-proBNP in patients with severe heart failure. Clin Chem 54: 858-65.
18. Heublein DM, Huntley BK, Boerrigter G, Cataliotti A, Sandberg SM, et al. (2007) Immunoreactivity and guanosine 3′,5′-cyclic monophosphate activating actions of various molecular forms of human B-type natriuretic peptide. Hypertension 49: 1114-9.
19. Menon SG, Mills RM, Schellenberger U, Saqhir S, Protter AA, (2009) Clinical implications of defective B-type natriuretic peptide. Clin Cardiol 32: E36-41.